Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Mid and small cap stocks lead the gain
Thu, 27 Mar 11:30 am

The Indian stock markets gained momentum led by continuous buying from index heavyweights during the previous two hours of trade. Banking and power stocks are leading the pack of gainers.

The BSE Sensex is trading higher 113 points and the NSE-Nifty is trading higher 38 points. The BSE Mid Cap index is trading up by 0.7% and the BSE Small Cap index is trading up 1.2%. The rupee is trading at 60.17 to the US dollar.

Majority of telecom stocks are trading higher today. Himachal Futuristic and Bharti Airtel are leading the pack of gainers.

As per a leading business daily, mobile carriers in Africa plan to sell their telecom tower assets. The move is to reduce their exposure to reasonably expensive infrastructure in building mobile network. Indian telecom major Bharti Airtel is planning to sell its 15,000 telecom towers across 17 countries in the African continent. The tower assets is valued in the range of US$ 2 bn to US$ 2.5 bn. The other companies that also plan to offload the tower assets in the continent include MTN Group and Orange SA. Notably, tower assets are more expensive to run in the African continent as compared to other parts of the world. That's because, the need for backup generators and batteries to guard against power failure is a common phenomenon in the African region. For instance, telecom tower and allied infrastructure account for about 60% of the entire expenditure to build up a mobile network.

Indian pharma stocks are trading on a mixed note. While Panacea Biotech is trading higher, Biocon and Dr. Reddy's are trading weak.

As per a leading business daily, fresh trouble looms for Sun Pharma on the Taro Pharma's front, its Israelian subsidiary. The Indian drug maker plans to get two of its nominees re-elected as independent directors to the Taro board. In this regard, Sun Pharma is expected to face major opposition from the minority shareholders. The re-election on voting came up at the Taro's extraordinary general meeting. The extraordinary meeting has come up following a lawsuit filed against the company by BlueMountain and IsZo Capital, two of the company's largest minority shareholders. Notably, there has been various oppositions from minority shareholders ever since Sun's offer of US$ 464 m to acquire Taro during 2007.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid and small cap stocks lead the gain". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.